Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study

Launched by SIED KEBIR · Apr 24, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how a person's sense of smell (olfactory function) might help predict how well they will do after being diagnosed with glioblastoma, a type of brain cancer. Researchers will test patients' smell ability at different points during their treatment and compare it to their overall survival and cognitive abilities, which means how well they think and process information. They will also check how the disease and treatment affect patients' quality of life and mental well-being. To better understand the results, they will also include a group of people without brain tumors for comparison.

To participate in this study, individuals need to be at least 18 years old and newly diagnosed with glioblastoma, meaning they haven't had any prior chemotherapy or radiation for this condition. They should also have a good level of physical functioning. However, people with certain other health issues like severe brain injuries or neurodegenerative diseases, as well as those who have lost their sense of smell due to previous infections, cannot join. Participants can expect to undergo smell tests, cognitive assessments, and surveys about their quality of life during the trial, helping researchers gain valuable insights into the disease and its effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • At least 18 years of age
• • Newly-diagnosed glioblastoma (IDH wild-type)
• • Never received prior chemotherapy
• • Never received radiotherapy to the head or neck before
• • KPS ≥ 70
• • No history of severe head or brain trauma requiring ICU admission or classified as Glasgow Coma Scale grade 3
• • No respiratory infection at the time of inclusion
• • No significant aphasia
• Exclusion Criteria:
• • Presence of Neurodegenerative diseases (e.g. Parkinson's disease, Alzheimer's disease, Huntington's disease, Korsakoff's syndrome, Pick's disease, Shy-Drager syndrome)
• • History of invasive tumors or surgery in the head or neck area, except for surgeries for non-invasive skin tumors (e.g. basal cell carcinomas)
• • Permanent olfactory impairment following infections (e.g., influenza, coronavirus)
• • Conditions that, in the examiner's judgment, could interfere with the participant's study compliance (e.g., schizophrenia)
• • Language barriers likely to interfere with participation or comprehension of study procedures.